Mechanism of Saikosaponin D in regulating ferroptosis in patient-derived lung adenocarcinoma organoids via upregulation of ATF3/CHOP/CHAC1 signaling
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Lung adenocarcinoma (LUAD) is associated with high morbidity and mortality, making the discovery of novel and effective drugs treatment crucial.This study aimed to identify and evaluate antitumor saponin monomers with better effects using patient-derived organoid (PDO) models from patients with LUAD. We successfully constructed LUAD PDO models and confirmed their similarity to original tissues using immunohistochemistry and immu-nofluorescence staining. We performed drug sensitivity screening using the CCK-8 assay on five kinds of saponin monomers. saikosaponin D (SSD) was identified as having the highest antitumor potential and we then validated its efficacy. The antitumor mechanism of the saponin monomer was elucidated using RNA sequencing and confirmed using flow cytometry, ferrous ion determi-nation, RT-qPCR, western blotting, molecular docking and drug affinity responsive target stability experiment. SSD exhibited concentration-dependent inhibition of PDO viability in LUAD and inhibited proliferation and mi-gration of A549 lung cancer cells. Mechanistically, the results from the PDO and A549 cell ex-periments were consistent with those of the RNA sequencing analysis, indicating that SSD upreg-ulated the ATF3/CHOP/CHAC1 pathway, triggered endoplasmic reticulum stress, and induced ferroptosis. We demonstrate that SSD exerted stronger antitumor effects than cis-platin. These findings lay the groundwork for the potential application of SSD in the treatment of LUAD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Mechanism of Saikosaponin D in regulating ferroptosis in patient-derived lung adenocarcinoma organoids via upregulation of ATF3/CHOP/CHAC1 signaling
- Date Crossref
- 31/01/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chengdu University of Traditional Chinese Medicine TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province pays non établi dans la noticeUniversité ou école supérieure
-
Sichuan University Department of Laboratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
West China Hospital of Sichuan University pays non établi dans la noticeÉtablissement de santé
-
Sichuan Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Second Affiliated Hospital of Chengdu University of Traditional Chinese pays non établi dans la noticeÉtablissement de santé
-
School of Medicine Department of Thoracic Surgery pays non établi dans la noticeUniversité ou école supérieure
TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province — Chengdu University of Traditional Chinese Medicine, Department of Laboratory Medicine — Sichuan University et West China Hospital of Sichuan University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.